Enliven Therapeutics, Inc. (ELVN)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Richard A. Fair M.B.A.
|
CEO, President & Director | 672.66k | -- | 1969 |
|
Mr. Samuel S. Kintz M.B.A.
|
Co-Founder & Head of Pipeline | 956.09k | -- | 1986 |
|
Mr. Benjamin Hohl
|
CFO & Head of Corporate Development | 667.89k | -- | 1989 |
|
Dr. Helen Louise Collins M.D.
|
Chief Medical Officer | 726.42k | -- | 1963 |
|
Dr. Joseph P. Lyssikatos Ph.D.
|
Co-Founder & Research Fellow | 709.4k | -- | 1965 |
|
Mr. Anish Patel Pharm.D.
|
Co-Founder & COO | -- | -- | 1981 |
|
Dr. Galya D. Blachman Esq., Ph.D.
|
Chief Legal Officer & Head of Business Development | -- | -- | 1977 |
|
Damiette Smit
|
Vice President of Clinical Development | -- | -- | -- |
Enliven Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 67
Description
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.
Corporate Governance
Upcoming Events
November 11, 2026 at 8:00 PM UTC
Enliven Therapeutics, Inc. Earnings Date
